Walgreens PSC gains nearly 125,000 customers
DEERFIELD, Ill. — After announcing a special discount for Express Scripts members on the annual membership fee for the Walgreens Prescription Savings Club, the drug store chain said its PSC gained nearly 125,000 customers in the first week of the new year.
Noting the "record numbers of daily sign-ups," Walgreens said its program is designed to help patients who are covered by an Express Scripts pharmacy network continue using Walgreens when possible or make a smooth transition to another community pharmacy. PSC offers savings on more than 8,000 brand-name and all generic medications, with more than 400 generic medications offered as three-month supply for less than $1 a week.
“Our customers are looking for ways to continue using Walgreens to preserve their relationship with their trusted Walgreens pharmacist,” said Kermit Crawford, Walgreens president of pharmacy, health and wellness solutions and services. “They appreciate the access we provide, including 24-hour service and having the medication they need in stock. For many of these medications, especially generics, customers are finding our PSC card is very cost competitive.”
PSC is an existing Walgreens drug discount program, with nearly 2 million people enrolled.
Bristol-Myers Squibb to acquire Inhibitex
NEW YORK — Bristol-Myers Squibb is buying Inhibitex for $2.5 billion, the companies said.
In a $26-per-share tender offer, Bristol will acquire the Alpharetta, Ga.-based developer of treatments for hepatitis C. Inhibitex’s lead product is INX-189, an orally administered drug currently in phase-2 clinical trials.
"The acquisition of Inhibitex builds on Bristol-Myers Squibb’s long history of discovering, developing and delivering innovative new medicines in virology and enriches our portfolio of investigational medicines for hepatitis C," Bristol CEO Lamberto Andreotti said. "There is significant unmet medical need in hepatitis C. This acquisition represents an important investment in the long-term growth of the company."
Mylan seeks approval for generic diabetes drug
PITTSBURGH — Generic drug maker Mylan is challenging the patent on a drug used to treat diabetes, the company said Monday.
Mylan said that it was sued by Takeda Pharmaceutical, Watson Pharmaceuticals and Andrx Labs in the U.S. District Court for the Southern District of New York in response to Mylan’s filing a regulatory approval application with the Food and Drug Administration for a generic version of Actoplus Met XR (pioglitazone hydrochloride and metformin hydrochloride) extended-release tablets in the 15-mg/1,000-mg and 30-mg/1,000-mg strengths.
The application contained a paragraph IV certification, a legal assertion that Actoplus Met XR’s patent protection is invalid, unenforceable or won’t be infringed.
Actoplus Met XR had sales of about $21.4 million in the two strengths during the 12-month period ended in September, according to IMS Health.